Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial

Authors

Linda F. Stein Gold, Henry Ford HealthFollow
Kim Papp
David Pariser
Neal Bhatia
Howard Sofen
Lorne Albrecht
Melinda Gooderham
Kristina Callis Duffin
Mindy Chen
Maria Paris
Sue Cheng
Hernan Picard
Yao Wang
Lawrence Green

Recommended Citation

Gold LS, Papp K, Pariser D, Bhatia N, Sofen H, Albrecht L, Gooderham M, Duffin KC, Chen M, Paris M, Cheng S, Picard H, Wang Y, and Green L. Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial. J Am Acad Dermatol 2023; 88(2):430-433.

Document Type

Article

Publication Date

2-1-2023

Publication Title

J Am Acad Dermatol

PubMed ID

Not assigned.

Volume

88

Issue

2

First Page

430

Last Page

433